Products
« APTIMA COMBO 2® Assay
« APTIMA® CT Assay
« APTIMA® GC Assay
« APTIMA® HPV Assay
« APTIMA® HCV RNA Qualitative Assay
« APTIMA® HIV-1 RNA Qualitative Assay
« PROGENSA® PCA3 Assay
Products Line « Molecular Biology « TMA Assays
Print Page Print
APTIMA COMBO 2® Assay
Description

The APTIMA COMBO 2® Assay is a target amplification nucleic acid probe test that utilizes target capture for the in vitro qualitative detection and differentiation of ribosomal RNA (rRNA) from Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (GC) to aid in the diagnosis of chlamydial and/or gonococcal urogenital disease.
The APTIMA COMBO 2 Assay virtually eliminates inhibition problems and cross-reactivity, offers multiplex detection and differentiation and also improves workflow and throughput. The testing solution is cost-effective by providing two results from one sample and also increases laboratory efficiency with single tube testing. Use of the assay provides clinicians with the appropriate tools to be able to significantly reduce the prevalence and incidence of CT and GC infections in sexually active individuals as well as prevent their serious and costly results.
The sensitivity of the APTIMA COMBO 2 Assay has been shown to be superior to culture and direct specimen tests. The greater sensitivity of the test permits the use of specimens other than endocervical swabs for women and urethral swabs for men. It is the only assay with urine specimen sensitivity equivalent to swab specimen. Additionally, excellent sensitivity and specificity has been demonstrated with vaginal swabs and liquid Pap specimens in the APTIMA COMBO 2 Assay.
 

logo logo logo logo logo
About Us | Product Lines WiseGroup Website Development